Buy bk-2c-b for sale online - USA vendor

βk-2C-B: A Unique Psychedelic Phenethylamine

βk-2C-B, also known as Bk-2C-B or beta-keto 2C-B, stands out as a novel psychedelic substance within the phenethylamine class. This compound represents a structural analog of 2C-B.

Subjective Effects: A Closer Look

The subjective effects associated with βk-2C-B are diverse, encompassing open and closed-eye visuals, temporal distortion, euphoria, and ego dissolution. It is worth noting that, in comparison to 2C-B, βk-2C-B tends to exhibit heightened stimulation and reduced psychedelic characteristics, accompanied by a significantly extended duration of action.

A Novel and Mysterious Substance

βk-2C-B remains relatively rare, with minimal historical usage documented before its emergence in 2014 through online vendors, who marketed it as a research chemical.

The Need for Caution: Lack of Data

Extremely limited data concerning the pharmacological attributes, metabolism, and toxicity of βk-2C-B is available. Consequently, individuals contemplating its use are strongly urged to approach this enigmatic hallucinogenic compound with great caution and adopt harm reduction practices.

Exploring the History and Cultural Context

Contrary to many 2C-x compounds, the original synthesis of βk-2C-B is not publicly disclosed, and it is not attributed to Alexander Shulgin in the 1970s.

The earliest reputable reference to βk-2C-B emerges in 2004, primarily within the context of a scientific study focused on its role as a precursor for 5-HT2A serotonin receptor agonists. Subsequently, the substance reappears in December 2007, when the user "King Kong" initiated a discussion on the bluelight.org forum regarding bk-2c-bβk-2C-B.

Interest in βk-2C-B intensified after 2013, concurrent with its introduction to the research chemical market via online head shops, where it was marketed as a legal alternative to 2C-B.

Despite these developments, βk-2C-B remains relatively obscure, even among research chemicals. An analysis of Google search trends from 2013 to 2017 reveals that 2C-B was consistently searched three to four times more often than βk-2C-B. Furthermore, since 2017, βk-2C-B appears to have nearly vanished from the open market.

Delving into the Chemistry

βk-2C-B, or beta-keto 2C-B, is a phenethylamine derivative featuring a phenyl ring connected to an amino (NH2) group by way of an ethyl chain. This compound presents a ketone group at the beta carbon (R1) of the 2C-B structure, along with methoxy functional groups (CH3O-) attached to carbons R2 and R5. Additionally, a bromine atom is affixed to carbon R4 of the phenyl ring. βk-2C-B falls within the 2C family of phenethylamines, characterized by methoxy groups at the 2 and 5 positions of the benzene ring.

Unraveling Pharmacological Mechanisms

The primary mode of action for βk-2C-B is believed to be as a 5-HT2A partial agonist. It is thought that its psychedelic effects stem from this interaction with the 5-HT2A receptors. However, the precise mechanisms underlying these interactions and their role in generating the psychedelic experience remain elusive.

Subjective Effects of βk-2C-B

Physical Effects

• Spontaneous tactile sensations
• Increased heart rate
• Nausea
• Pupil dilation

Visual Effects

Enhancements

• Colour enhancement
• Pattern recognition enhancement
• Visual acuity enhancement

Distortions

• Drifting (melting, breathing, morphing, and flowing)
• Colour shifting
• Depth perception distortions
• Perspective distortions
• Symmetrical texture repetition
• Tracers
• After images
• Brightness alteration
• Diffraction

Geometry

Hallucinatory States

• Transformations
• Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations, scenarios, and plots)

Cognitive Effects

• Conceptual thinking
• Cognitive euphoria
• Delusion
• Emotion enhancement
• Immersion enhancement
• Increased music appreciation
• Memory suppression
• Ego death
• Novelty enhancement
• Personal bias suppression
• Thought loops
• Time distortion
• Unity and interconnectedness

Auditory Effects

Enhancements

Distortions

Hallucinations

Toxicity and Harm Potential

The toxicity and long-term health effects of recreational βk-2C-B use seem unexplored in scientific research, and the precise toxic dose remains elusive. This knowledge gap is due to βk-2C-B's classification as a research chemical with minimal documented human usage history. Anecdotal evidence from the psychonaut community suggests that trying βk-2C-B in isolation at low to moderate doses carries no immediate negative health repercussions. However, it's essential to exercise caution, and independent research is advised when considering combinations with other substances.

Utilizing harm reduction practices is strongly recommended when using this substance.

Tolerance and Addiction Potential

βk-2C-B, like most psychedelics, is not habit-forming, and the inclination to use it may, in fact, diminish with continued use. Tolerance to its effects develops almost immediately post-ingestion. Subsequently, it takes approximately 3 days for tolerance to halve and around 7 days to return to baseline (in the absence of further consumption). Bk-2C-B demonstrates cross-tolerance with all psychedelics, leading to a diminished effect following βk-2C-B consumption.

Legal Status

• Canada: βk-2C-B was classified as a Schedule III controlled substance on October 12, 2016.
• Germany: βk-2C-B is governed by the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production, import with the intention to market, administration to others, and trading are punishable. Possession is illegal but not penalized.
• Japan: βk-2C-B was designated as a controlled substance in Japan effective March 25th, 2015.
• Switzerland: βk-2C-B is specifically named as a controlled substance under Verzeichnis E.
• Sweden: βk-2C-B was categorized as a narcotic on April 5, 2019.
• United Kingdom: The production, supply, or import of this drug is illegal under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
• United States: βk-2C-B remains unscheduled in the U.S., but it may be considered an analogue of 2C-B under the Federal Analogue Act, potentially leading to its classification as a Schedule I drug.